Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Health care professionals should inform sensitive patients about the risks of exposure to air pollutants

If you have some form of lung or cardiovascular disease, has your doctor told you how to check today's "AQI", and what to do if it's over 100?

11 May 2007

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Bristol-Myers Squibb Company and Isis Pharmaceuticals have announced a collaboration to discover, develop and commercialize novel antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for the prevention and treatment of cardiovascular disease.

10 May 2007

Ischemic-targeted approach to angioplasty among asymptomatic survivors of heart attack

When compared with intensive drug therapy, percutaneous coronary intervention (PCI, angioplasty) was more beneficial in reducing the long-term risk of major cardiac events among heart attack survivors with "silent ischemia", according to a study in the May 9 issue of Journal of the American Medical Association.

9 May 2007

High intracoronary attenuation significantly improves diagnostic accuracy in 64-slice CT-CA of the coronary arteries

For the study, 170 patients with suspected coronary artery disease underwent CT-CA. The average vascular attenuation measured in the aortic root and in coronary arteries was used to divide the population into two groups of 85 patients each, one with low attenuations and one with high.

8 May 2007

Variants of two genes involved in the inflammatory system linked to cognitive decline after heart surgery

Duke University Medical Center researchers believe their findings could help physicians identify patients at risk of suffering mental decline after heart surgery and raises the possibility that these patients could be treated with drugs that are known to dampen the inflammatory response.

2 May 2007

Aspirin appears to be less effective heart treatment for women than men

A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.

30 Apr 2007

Heart transplant patients benefit from new approach to immunosuppression

A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies.

27 Apr 2007

Aspirin therapy for coronary artery disease less effective for women than men

A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.

27 Apr 2007

New data supports safety of ranolazine but not its effectiveness

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA .

25 Apr 2007

Ranolazine safe but not effective in reducing major cardiac events in ACS patients

25 Apr 2007

Eating regularly in some fast-food restaurants unsafe

Eating regularly in some fast-food chain outlets is unsafe in many parts of the world, top Danish research experts warn today.

24 Apr 2007

Are higher doses and higher costs for cholesterol drugs worth the extra money?

When it comes to cholesterol-lowering drugs, more is better. At least, that's what heart doctors and heart patients have been hearing in recent years.

24 Apr 2007

Risk and outcome similar for bypass surgery, drug-eluting stents

Drug-eluting stent therapy and bypass surgery for coronary artery disease have about the same risk for a major cardiac event within 30 days after the procedures, researchers reported at the American Heart Association's 8th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology.

20 Apr 2007

Gene finding could lead to new pathways for development of Alzheimer's therapeutics

Scientists have known for more than a decade that individuals with a certain gene are at higher risk for developing Alzheimer's disease.

11 Apr 2007

Long-term safety of drug-eluting stents in off-label use

Research presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent - a dangerous complication - and adherence and responsiveness to anti-clotting medication.

3 Apr 2007

Trial of percutaneous coronary intervention added to optimal medical therapy in patients with stable coronary heart disease

Percutaneous coronary interventions (PCI) involve opening partially blocked arteries to improve blood flow to the heart. These procedures are performed more than 1 million times a year.

3 Apr 2007

Effect of Torcetrapib on the progression of coronary atherosclerosis

Investigators report that torcetrapib, a drug that substantially raises high-density lipoprotein cholesterol or HDL (the "good" cholesterol), did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe (IVUS).

2 Apr 2007

Addition of torcetrapib to statin therapy has no benefit for atherosclerosis progression

For some patients with high cholesterol, even the most aggressive treatment with statin drugs fails to prevent coronary artery disease.

2 Apr 2007

African Americans may be at higher risk of heart failure because of racial variations in heart muscle's pumping ability

Scientists have known for nearly a decade that African Americans have higher rates of hospitalization for heart failure than other major U.S. racial or ethnic groups, but until now they have had limited information other than socio-economic and demographic characteristics to explain why this is so.

2 Apr 2007

Coronary procedure adds no benefit over 'optimal medical therapy' alone

Percutaneous coronary intervention plus optimal medical therapy does not improve outcomes in patients with coronary artery disease, compared with optimal medical therapy alone, according to study results presented at the 56th Annual Scientific Session of the American College of Cardiology in New Orleans, and published online in the New England Journal of Medicine.

1 Apr 2007

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Health care professionals should inform sensitive patients about the risks of exposure to air pollutants

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Ischemic-targeted approach to angioplasty among asymptomatic survivors of heart attack

High intracoronary attenuation significantly improves diagnostic accuracy in 64-slice CT-CA of the coronary arteries

Variants of two genes involved in the inflammatory system linked to cognitive decline after heart surgery

Aspirin appears to be less effective heart treatment for women than men

Heart transplant patients benefit from new approach to immunosuppression

Aspirin therapy for coronary artery disease less effective for women than men

New data supports safety of ranolazine but not its effectiveness

Ranolazine safe but not effective in reducing major cardiac events in ACS patients

Eating regularly in some fast-food restaurants unsafe

Are higher doses and higher costs for cholesterol drugs worth the extra money?

Risk and outcome similar for bypass surgery, drug-eluting stents

Gene finding could lead to new pathways for development of Alzheimer's therapeutics

Long-term safety of drug-eluting stents in off-label use

Trial of percutaneous coronary intervention added to optimal medical therapy in patients with stable coronary heart disease

Effect of Torcetrapib on the progression of coronary atherosclerosis

Addition of torcetrapib to statin therapy has no benefit for atherosclerosis progression

African Americans may be at higher risk of heart failure because of racial variations in heart muscle's pumping ability

Coronary procedure adds no benefit over 'optimal medical therapy' alone

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in